中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu

Vol.40 No.9 (287 in total) Sep. 2024
Theme Issue: Conversion Therapy of Hepatocellular Carcinoma
Executive Chief Editor: CAI Jianqiang  

National Cancer Center； National Clinical Research Center for Cancer； Department of Hepatobiliary

Surgery， Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College

Cover Content

 Previous Issue | Next Issue 

Display Method:
Editorial
The therapeutic paradigm of liver surgery in the era of conversion therapy
Xinyu BI, Jianqiang CAI
2024, 40(9): 1721-1724. DOI: 10.12449/JCH240901
Abstract(459) HTML (2470) PDF (571KB)(96)
Abstract:
Surgical resection remains the best approach for achieving long-term survival in patients with hepatocellular carcinoma （HCC）； however， due to the low early diagnosis rate of HCC patients in China， only 15%-20% of the patients are eligible for surgical resection at the time of initial diagnosis. Eve...
Expert Forum
Strategies and practice of conversion therapy for hepatocellular carcinoma
Chi MA, Guang TAN
2024, 40(9): 1725-1731. DOI: 10.12449/JCH240902
Abstract(452) HTML (2104) PDF (683KB)(102)
Abstract:
Due to the insidious onset and poor prognosis of primary liver cancer， most patients are found to have unresectable primary liver cancer at initial diagnosis. In recent years， with the advent of targeted therapy， immunotherapy， and local therapy， some patients with advanced liver cancer have achieve...
Value of local treatment combined with systemic therapy in conversion therapy for hepatocellular carcinoma
Chaofan ZHU, Xiaodong WANG
2024, 40(9): 1732-1737. DOI: 10.12449/JCH240903
Abstract(289) HTML (1609) PDF (664KB)(72)
Abstract:
Hepatocellular carcinoma （HCC） is one of the most common malignant tumors in clinical practice. Due to the lack of typical clinical manifestations in the early stage， most patients in China are in the advanced stage at the time of confirmed diagnosis and thus lose the opportunity for surgical resect...
Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma
Shichun LU
2024, 40(9): 1738-1740. DOI: 10.12449/JCH240904
Abstract(430) HTML (1614) PDF (531KB)(76)
Abstract:
With the continuous emergence of biotherapy drugs in recent years， great progress has been made in the systemic therapy for advanced liver cancer. Immune checkpoint inhibitors combined with anti-angiogenic targeted drugs has become the first-line regimen recommended for the treatment of advanced liv...
Hotspot·Perspective·Viewpoint
The way is simple： A brief natural history of chronic hepatitis B virus infection and disease progression
Xin LIU, Jia LI, Fengmin LU
2024, 40(9): 1741-1745. DOI: 10.12449/JCH240905
Abstract(485) HTML (1353) PDF (958KB)(148)
Abstract:
Chronic hepatitis B virus （HBV） infection is the major cause of chronic hepatitis B （CHB）， liver cirrhosis， and primary hepatocellular carcinoma （HCC） and brings huge health and economic burdens to the society. The disease progression of CHB is driven by the interaction between the virus， host immun...
Guideline
Multidisciplinary expert consensus on bicyclol in prevention and treatment of inflammatory liver injury
Hepatology Group， Chronic Disease Management Branch， China Medicinal Biotechnology Association
2024, 40(9): 1746-1756. DOI: 10.12449/JCH240906
Abstract(464) HTML (1443) PDF (1027KB)(147)
Abstract:
Inflammatory liver injury is the initiating factor for various chronic liver diseases. It can involve the whole body， and on the contrary， systemic diseases may also lead to liver injury. The diagnosis and treatment of liver disease should not only consider the liver disease itself， but also underst...
Experts consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of primary biliary cholangitis
Expert Committee on Hepatology， Doctor Society of Integrative Medicine， Chinese Medical Doctor Association
2024, 40(9): 1757-1766. DOI: 10.12449/JCH240907
Abstract(604) HTML (1142) PDF (1098KB)(216)
Abstract:
Primary biliary cholangitis （PBC） is a chronic autoimmune liver disease. In recent years， related studies in China and globally have provided some evidence-based medical evidence for the integrated traditional Chinese and Western medicine treatment of PBC. Based on the latest diagnosis and treatment...
Guideline Interpretation
An excerpt of clinical practice guideline of prevention and treatment of metabolic dysfunction-associated （non-alcoholic） fatty liver disease （2024 edition）
Jianing KONG, Binbin ZHANG, Junping SHI
2024, 40(9): 1767-1770. DOI: 10.12449/JCH240908
Abstract(2739) HTML (1321) PDF (553KB)(1041)
Abstract:
With further in-depth studies on non-alcoholic fatty liver disease （NAFLD）， new evidence， concepts， and methods continue to emerge. Chinese Society of Hepatology， Chinese Medical Association， comprehensively updated and revised the previous guidelines based on the latest research advances in fatty l...
Fatty Liver Disease
Levels and clinical significance of urinary lead in patients with nonalcoholic fatty liver disease
Yajie LIU, Ruilin WANG
2024, 40(9): 1771-1777. DOI: 10.12449/JCH240909
Abstract(347) HTML (147) PDF (785KB)(35)
Abstract:
Objective To investigate the association between urinary lead and nonalcoholic fatty liver disease （NAFLD）. Methods The participants， aged ≥18 years， were selected from the 2017‍ ‍—‍ ‍2020 National Health and Nutrition Examination Survey （NHANES）， with the exclusion of the participants with a lack o...
Autoimmune Liver Disease
Clinical features of primary biliary cholangitis patients with negative or positive anti-mitochondrial antibody： A comparative study
Kexin QIAO, Guiqin ZHOU, Yaxing LIU, Ying FENG, Yao LIU, Bin LI, Xianbo WANG
2024, 40(9): 1778-1784. DOI: 10.12449/JCH240910
Abstract(356) HTML (169) PDF (693KB)(41)
Abstract:
Objective To investigate the differences in clinical features between the primary biliary cholangitis （PBC） patients with negative or positive anti-mitochondrial antibody （AMA） by analyzing related immune and biochemical parameters. Methods This study was conducted among the patients who attended Be...
Liver Fibrosis and Liver Cirrhosis
Diagnostic value of serum extra-spindle pole-like protein 1 in the progression of hepatitis B virus-related liver fibrosis
Long HUANG, Hongqian LIANG, Aoli REN, Minghua SU, Bobin HU, Qingmei LI, Tumei SU, Qianbing YIN, Yanfei FENG, Jianning JIANG
2024, 40(9): 1785-1789. DOI: 10.12449/JCH240911
Abstract(312) HTML (1024) PDF (896KB)(26)
Abstract:
Objective To investigate the clinical diagnostic value of extra-spindle pole-like protein 1 （ESPL1） in the progression of hepatitis B virus （HBV）-related liver fibrosis. Methods A total of 228 patients with HBV infection who were admitted to The First Affiliated Hospital of Guangxi Medical Universit...
Establishment of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis patients with normal aminotransferases aged ≤30 years
Qingrong TANG, Changxiang LAI, Fang WANG, Jin LU, Chunhua XU, Xiangjun LI, Yizhou XU
2024, 40(9): 1790-1795. DOI: 10.12449/JCH240912
Abstract(339) HTML (137) PDF (831KB)(31)
Abstract:
Objective To establish a noninvasive diagnostic model for liver fibrosis in chronic hepatitis B （CHB） patients with normal alanine aminotransferase （ALT） and an age of ≤30 years by selecting specific indicators from the commonly used noninvasive indicators such as clinical， biochemical， and imaging ...
Risk factors for unplanned readmission after transjugular intrahepatic portosystemic shunt in cirrhotic patients with esophagogastric variceal bleeding and construction of a nomogram model
Qin YIN, Zhaorong WU, Feng ZHANG, Chunyan JIN, Yanping CAO, Jiangqiang XIAO, Yuzheng ZHUGE, Qian WANG
2024, 40(9): 1796-1801. DOI: 10.12449/JCH240913
Abstract(323) HTML (1097) PDF (1108KB)(34)
Abstract:
Objective To investigate the risk factors for unplanned readmission within 30 days after discharge in cirrhotic patients with esophagogastric variceal bleeding undergoing transjugular intrahepatic portosystemic shunt （TIPS）， and to construct a nomogram predictive model. Methods A total of 241 cirrho...
Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model
Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO
2024, 40(9): 1802-1806. DOI: 10.12449/JCH240914
Abstract(304) HTML (96) PDF (760KB)(27)
Abstract:
Objective To investigate the risk factors for portopulmonary hypertension （POPH） in liver cirrhosis， and to construct a noninvasive predictive model. Methods A retrospective analysis was performed for the clinical data of 310 cirrhotic patients with portal hypertension who were hospitalized in The T...
Liver Neoplasm
Efficacy and safety of microwave ablation versus hepatic resection in treatment of hepatocellular carcinoma with liver cirrhosis： A Meta-analysis
Jianxing LUO, Yang ZHANG, Ne XIANG, Xiaoyu HU
2024, 40(9): 1807-1815. DOI: 10.12449/JCH240915
Abstract(383) HTML (119) PDF (2928KB)(32)
Abstract:
Objective To investigate the efficacy and safety of microwave ablation （MWA） versus hepatic resection （HR） in the treatment of hepatocellular carcinoma （HCC） with liver cirrhosis using a meta-analysis. Methods This study was conducted according to the PRISMA guideline， with a PROSPERO registration n...
Construction and validation of a risk prediction model for postoperative delirium in primary liver cancer patients aged 60 years or older
Yao MA, Ting LI, Qiushi ZHANG, Ling HU, Jie. ZHENG
2024, 40(9): 1816-1821. DOI: 10.12449/JCH240916
Abstract(261) HTML (115) PDF (799KB)(27)
Abstract:
Objective To construct a risk prediction model for postoperative delirium in elderly patients with primary liver cancer， and to validate its application value. Methods A retrospective analysis was performed for 175 elderly patients with primary liver cancer who were admitted to Tianyou Hospital Affi...
Construction of a novel disulfidptosis-related prognostic model for patients with hepatocellular carcinoma based on bioinformatics analysis
Zheng SONG, Wei LUO, Xiujuan CHANG, Yongping YANG
2024, 40(9): 1822-1832. DOI: 10.12449/JCH240917
Abstract(495) HTML (1031) PDF (6149KB)(28)
Abstract:
Objective To investigate the expression of disulfidptosis-related genes in hepatocellular carcinoma （HCC） and the prognostic value of disulfidptosis in HCC， to construct a prognostic model， and to analyze its impact on the biological processes of HCC and sorafenib resistance. Methods The TCGA-LIHC d...
Expression of AU-rich element RNA-binding factor 1 in hepatocellular carcinoma and its value in prognostic evaluation
Yuan DUAN, Ting ZHANG, Jing ZHANG, Guiwen GUAN, Jingzhou WANG, Xiangmei CHEN
2024, 40(9): 1833-1839. DOI: 10.12449/JCH240918
Abstract(262) HTML (990) PDF (4247KB)(15)
Abstract:
Objective To investigate the effect of AU-rich element RNA-binding factor 1 （AUF1） on the proliferation， apoptosis， and migration abilities of hepatocellular carcinoma （HCC） cells and possible mechanisms， and to clarify the role and molecular mechanism of AUF1 in the progression of HCC. Methods The ...
Mechanism of action of cinobufotalin in inhibiting lung metastasis of hepatocellular carcinoma by regulating AKT-mediated epithelial-mesenchymal transition in a nude mouse model
Yue YANG, Siyu XU, Jue WANG, Shilin DU, Chunlei ZHANG, Haiyan SONG
2024, 40(9): 1840-1847. DOI: 10.12449/JCH240919
Abstract(297) HTML (130) PDF (3425KB)(26)
Abstract:
Objective To investigate the effect and mechanism of cinobufotalin in inhibiting hepatocellular carcinoma （HCC） metastasis by regulating epithelial-mesenchymal transition （EMT）. Methods A total of 36 male BALB/c nude mice， aged 6 weeks， were given injection of MHCC97H cells via the caudal vein to es...
Pancreatic Disease
Correlation of the serum levels of adiponectin， omentin， and visfatin with the severity of acute pancreatitis
Xin XU, Zhangxing CHEN
2024, 40(9): 1848-1852. DOI: 10.12449/JCH240920
Abstract(240) HTML (91) PDF (910KB)(23)
Abstract:
Objective To investigate the correlation of the serum levels of adiponectin， omentin， and visfatin with the severity of acute pancreatitis （AP）. Methods Blood samples were collected from 35 healthy individuals in the control group and 70 patients with AP who were admitted to Chenggong Hospital Affil...
Construction of pancreatic cancer organoids and their sensitivity to chemotherapy drugs
Jingyu WANG, Rong HUANG, Yan LU, Ziran CHEN, Xiaojie ZHANG, Hu REN, Nan ZHANG, Dongbing ZHAO, Wei SONG, Xingguang ZHANG
2024, 40(9): 1853-1858. DOI: 10.12449/JCH240921
Abstract(431) HTML (126) PDF (3800KB)(47)
Abstract:
Objective To construct and identify a patient-derived organoid model， and to investigate the sensitivity of chemotherapy drugs using this model. Methods Pancreatic cancer cells were obtained from the surgical specimens of two female patients with a confirmed diagnosis of pancreatic cancer after tumo...
Value of preoperative alanine aminotransferase/aspartate aminotransferase combined with multi-phase CT radiological indicators in predicting clinically relevant pancreatic fistula after pancreaticoduodenectomy
Junhao PAN, Jian XIN, Chunhui WANG
2024, 40(9): 1859-1867. DOI: 10.12449/JCH240922
Abstract(276) HTML (142) PDF (2208KB)(21)
Abstract:
Objective To investigate the risk factors for clinically relevant postoperative pancreatic fistula （CR-POPF） after pancreaticoduodenectomy （PD）， and to establish a predictive model for early identification of CR-POPF. Methods A total of 244 patients who underwent PD in General Hospital of Northern T...
Case Report
Diagnosis and treatment of decompensated cirrhosis with multiple primary cancers： A case report
Wenting CHAO, Rui HUANG
2024, 40(9): 1868-1872. DOI: 10.12449/JCH240923
Abstract(332) HTML (142) PDF (1776KB)(73)
Abstract:
Multiple primary cancers （MPC） refer to the presence of more than one type of cancer with different histological features and sites in the same individual， and it is relatively rare in clinical practice. This article reports a case of decompensated cirrhosis with MPC and discusses the diagnosis， tre...
Review
The mechanism of compound traditional Chinese medicine prescriptions in reversal of liver fibrosis and early liver cirrhosis
Peng ZHANG, Shihao ZHENG, Siyuan GOU, Jinchi XIE, Xianzhao YANG, Yongan YE
2024, 40(9): 1873-1879. DOI: 10.12449/JCH240924
Abstract(431) HTML (1085) PDF (1070KB)(62)
Abstract:
Liver fibrosis and cirrhosis are the common outcomes of various chronic liver diseases after progression， and studies have shown that liver fibrosis and early liver cirrhosis can be reversed. Compound traditional Chinese medicine prescriptions have a marked therapeutic effect in reversing liver fibr...
Research advances in the intelligent medical imaging diagnosis of liver cancer
Jie XU, Wenbin XU, Keqing HE, Ding SHANGGUAN, Ting XU, Mingjun XIE, Nianbao LONG, Laian GE
2024, 40(9): 1880-1885. DOI: 10.12449/JCH240925
Abstract(487) HTML (232) PDF (906KB)(65)
Abstract:
Liver cancer is one of the most threatening diseases to the human body， and most patients are already in the advanced stage at the time of diagnosis， resulting in an extremely high mortality rate. The diagnosis and treatment of early-stage liver cancer is the key to improving the prognosis of patien...
Role of inflammatory cytokines in disorder of glucose metabolism in patients with liver cirrhosis
Yunchong WU, Yanyan YANG, Chuan LI, Xiaohuan WU, Shide LIN
2024, 40(9): 1886-1890. DOI: 10.12449/JCH240926
Abstract(256) HTML (127) PDF (658KB)(24)
Abstract:
In recent years， there has been a deeper understanding of the role and mechanisms of common inflammatory cytokines in the development and progression of liver cirrhosis， such as interleukin-1β， interleukin-6， interleukin-10， interleukin-17， tumor necrosis factor-α， interferon-γ， and C-reactive prote...
Current status of research on artificial intelligence in prognostic prediction models for acute-on-chronic liver failure
Wei JIANG, Xiujun CHANG, Fan ZENG, Yunping LAN
2024, 40(9): 1891-1896. DOI: 10.12449/JCH240927
Abstract(370) HTML (137) PDF (655KB)(51)
Abstract:
Acute-on-chronic liver failure （ACLF） is a complex clinical syndrome of acute liver function deterioration on the basis of chronic liver diseases， characterized by hepatic and/or extra-hepatic organ failure and a high short-term mortality rate. At present， there is still a lack of effective treatmen...
Regulatory mechanism of exosomes in liver failure and the application value in diagnosis and treatment
Hua TONG, Yue LUO, Yadong WANG
2024, 40(9): 1897-1901. DOI: 10.12449/JCH240928
Abstract(303) HTML (122) PDF (900KB)(26)
Abstract:
Exosomes are an important vehicle for mediating material transportation and information transmission between cells， and the exosomes derived from hepatocytes， liver stem cells or extrahepatic mesenchymal stem cells promote the recovery and regeneration of damaged hepatocytes by inhibiting immune inf...
Role of liver regeneration in the repair of liver injury induced by N-acetyl-p-aminophenol
Yinkang MO, Zihao FAN, Feng REN
2024, 40(9): 1902-1907. DOI: 10.12449/JCH240929
Abstract(437) HTML (1187) PDF (972KB)(53)
Abstract:
Liver regeneration plays a crucial role in the recovery after liver injury induced by N-acetyl-p-aminophenol （APAP）. After APAP overdose， the degree of regeneration increases with the extent of liver injury， leading to the resolution of liver injury and spontaneous recovery in most cases. However， s...
Pyroptosis： A new bridge connecting gut microbiota and liver diseases
Yijie ZHAO, Lu XIE, Yating ZHANG, Guangwei LIU
2024, 40(9): 1908-1915. DOI: 10.12449/JCH240930
Abstract(263) HTML (109) PDF (1609KB)(30)
Abstract:
Since the proposal of the concept of the gut-liver axis， a large number of studies have focused on exploring the connection between gut microbiota and liver disease； however， the idea of using pyroptosis as a hub to explore the intrinsic mechanism of gut-liver crosstalk is still in its infancy. This...
Research advances in the degradation of hepatic lipid droplets through the autophagy pathway
Rongzhi WANG, Linli WANG, Jingwen JIAO, Yunfei YU, Baolong LI
2024, 40(9): 1916-1923. DOI: 10.12449/JCH240931
Abstract(711) HTML (1581) PDF (1212KB)(64)
Abstract:
Autophagy is a highly conserved cellular degradation pathway that degrades lipid droplets through a process called “lipophagy”. Lipophagy can selectively recognize lipid substances and degrade them， promoting β oxidation and thereby maintaining the balance of intracellular lipid metabolism. The live...
Role of macrophages in the development and progression of primary biliary cholangitis
Zongqi DENG, Wenlin TAI
2024, 40(9): 1924-1928. DOI: 10.12449/JCH240932
Abstract(265) HTML (134) PDF (838KB)(29)
Abstract:
Primary biliary cholangitis （PBC） is a persistent inflammatory autoimmune liver disease characterized by inflammatory injury and cholestasis in the small intrahepatic bile ducts. At present， the exact pathogenesis of PBC remains unknown， but a consensus has been reached on the fact that PBC is the r...
Introduction of High - quality Articles in Foreign Journals
Hepatology｜Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α
2024, 40(9): 1766-1766. DOI: 10.12449/JCH2409.gwqkjpwzjj1
Abstract(148) HTML (81) PDF (910KB)(19)
Abstract:
Journal of Hepatology｜Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis
2024, 40(9): 1777-1777. DOI: 10.12449/JCH2409.gwqkjpwzjj2
Abstract(219) HTML (70) PDF (909KB)(15)
Abstract:
Journal of Hepatology｜Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer
2024, 40(9): 1872-1872. DOI: 10.12449/JCH2409.gwqkjpwzjj3
Abstract(143) HTML (68) PDF (875KB)(11)
Abstract:
Acknowledgements
Current reviewers
2024, 40(9): 1915-1915. DOI: 10.12449/JCH2409.zhixie
Abstract(122) HTML (65) PDF (873KB)(11)
Abstract:
    

The first journal specializing in hepatobiliary and pancreatic diseases in China

Supervisor：Ministry of Education of the People's Republic of China

Sponsor：Jilin University

Academic Support: Chinese Society of Hepatology，Chinese Medical Association

Address: 461 Xinjiang Road, Changchun

Submit：0431-88782044

Peer review：0431-88783542

Email：lcgdb@vip.163.com

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

YesterdayIP[2433]YesterdayPV[3993]TodayIP[1538]TodayPV[2317]Online[106]

Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd